Related Experiment Video
Updated: May 14, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[5-alpha reductase inhibitors and prostate cancer prevention]
1Department of Urology, Beijing Hospital, Chinese Ministry of Health, Beijing 100730, China. wanben2000@sina.com
Abstract:
5-alpha reductase inhibitors decrease the level of dihydrotestosterone (DHT) by inhibiting 5-alpha reductase. Trials on 5-alpha reductase inhibitors in prostate cancer prevention showed that they could significantly decrease the incidence of prostate cancer, but meanwhile increase high-grade cases as well. Recent studies demonstrated that 5-alpha reductase inhibitors could reduce not only the prostate volume but also the volume of Gleason grade 3 prostate cancer, which made easier the detection of higher-grade prostate cancer in the second biopsy. 5-alpha reductase inhibitors could also increase the sensitivity of prostate biopsy in detecting prostate cancer, particularly that of a higher grade. The evidence we have obtained leads to the conclusion that 5-alpha reductase inhibitors do not increase the incidence of high-grade prostate cancer, but on the contrary help its earlier detection.
Insights
5-alpha reductase inhibitors lower dihydrotestosterone (DHT) levels. While initially thought to increase high-grade prostate cancer, evidence suggests they aid in earlier detection of aggressive forms.
Area of Science:
- Urology
- Oncology
- Pharmacology
Context:
- 5-alpha reductase inhibitors are used to reduce dihydrotestosterone (DHT) levels.
- Previous prostate cancer prevention trials indicated a potential increase in high-grade cases with these inhibitors.
- Emerging research suggests a nuanced role in prostate cancer detection and management.
Purpose:
- To evaluate the effect of 5-alpha reductase inhibitors on prostate cancer incidence and grade.
- To clarify the impact of these inhibitors on the detection of high-grade prostate cancer.
- To assess the sensitivity of prostate biopsy in detecting higher-grade cancers under these inhibitors.
Summary:
- 5-alpha reductase inhibitors significantly decrease prostate cancer incidence.
- These agents reduce prostate volume and Gleason grade 3 cancer, facilitating the detection of higher-grade cancers.
- The inhibitors enhance prostate biopsy sensitivity, particularly for detecting aggressive prostate cancer.
Impact:
- 5-alpha reductase inhibitors do not increase the incidence of high-grade prostate cancer.
- These drugs facilitate earlier detection of aggressive prostate cancer.
- Improved diagnostic accuracy for high-grade prostate cancer through enhanced biopsy sensitivity.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Direct Renin Inhibitors
Cancer Prevention
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

